Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in TEM.
← Back to Free Index

TEM

Analysis as of: 2026-10-21
Tempus AI, Inc.
Tempus provides molecular diagnostics, AI-enabled clinical workflow software, and data products to physicians, health systems, and biopharma customers.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Regulated Data Flywheel, But Proof Still Matters
This is a credible healthcare AI platform-upgrade story, not yet a pure software rerating. The upside depends on turning lab scale, governed data, and workflow embed into durable higher-quality revenue without losing financial discipline.

Analysis

Thesis
Tempus can compound above market rates by turning each test, provider workflow, and biopharma engagement into governed data that supports higher-value diagnostics, monitoring, and regulated software-like revenue; the win condition is proving this mix shift fast enough that Tempus rerates as a healthcare AI platform rather than remaining a premium-priced diagnostics roll-up.
Last Economy Alignment
Cheaper AI increases the value of Tempus' governed clinical data, provider workflow embed, and regulated diagnostics more than it threatens pricing. The main risk is not seat compression but reimbursement, regulation, and trust slowing the data flywheel.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.2x (from 5 most recent analyses)
Reasoning
The upside does not require a heroic software rerating. Tempus can more than triple revenue if oncology testing stays strong, MRD becomes a bigger contributor, data and applications renew well, and workflow products gain audited action-layer economics. Even with a lower revenue multiple than today, equity can still compound well because the business would be larger, cleaner, and less dependent on one-off diagnostics volume.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The core risk is sequential rather than existential. Tempus must prove that improving profitability is durable, close and integrate Personalis cleanly, expand MRD and regulated AI products without reimbursement setbacks, and convert data/workflow promise into repeatable high-quality revenue. If one or two gates slip, revenue can still grow, but the platform rerating likely weakens faster than the business itself.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.69
They control hard-to-copy clinical data rights, lab outputs, and provider workflow links, so cheaper AI makes their dataset and decision tools more valuable. The real threat is slower reimbursement, regulation, or a trust failure that leaves them looking like a testing vendor instead of a healthcare AI rail.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$74.94
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case